# An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis

> **NCT00826514** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 62 (actual)

## Conditions studied

- Chronic Prostatitis With Chronic Pelvic Pain Syndrome

## Interventions

- **DRUG:** Tanezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00826514
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-25
- **Primary completion:** 2010-01-11
- **Final completion:** 2010-03-17
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2021-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00826514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00826514, "An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00826514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*